Stockscreener 앱 받기
46.96
4.12%
-2.02
시간 외 거래:
47.01
0.05
+0.11%
전일 마감가:
$48.98
열려 있는:
$48.33
하루 거래량:
4.08M
Relative Volume:
0.66
시가총액:
$8.43B
수익:
$1.36B
순이익/손실:
$-302.91M
주가수익비율:
-27.33
EPS:
-1.7182
순현금흐름:
$-219.93M
1주 성능:
-17.97%
1개월 성능:
-1.86%
6개월 성능:
-31.30%
1년 성능:
-23.12%
1일 변동 폭
$46.51
$48.60
1주일 범위
$46.51
$57.94
52주 변동 폭
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
명칭
Tempus Ai Inc
전화
800-976-5448
주소
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, HNGE
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
46.96 | 8.80B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
184.55 | 30.74B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
69.74 | 14.24B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
95.95 | 8.17B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
79.08 | 6.53B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Underperform |
| 2026-04-13 | 업그레이드 | TD Cowen | Hold → Buy |
| 2026-02-19 | 개시 | Mizuho | Outperform |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-10-20 | 개시 | Canaccord Genuity | Buy |
| 2025-09-02 | 개시 | H.C. Wainwright | Buy |
| 2025-04-21 | 개시 | BTIG Research | Buy |
| 2025-02-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | 재개 | TD Cowen | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Outperform |
| 2024-12-09 | 개시 | Guggenheim | Buy |
| 2024-11-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-08-12 | 개시 | Piper Sandler | Neutral |
| 2024-07-09 | 개시 | BofA Securities | Buy |
| 2024-07-09 | 개시 | JP Morgan | Overweight |
| 2024-07-09 | 개시 | Longbow | Buy |
| 2024-07-09 | 개시 | Loop Capital | Buy |
| 2024-07-09 | 개시 | Morgan Stanley | Overweight |
| 2024-07-09 | 개시 | Needham | Buy |
| 2024-07-09 | 개시 | Stifel | Buy |
| 2024-07-09 | 개시 | TD Cowen | Buy |
| 2024-07-09 | 개시 | William Blair | Outperform |
모두보기
Tempus Ai Inc 주식(TEM)의 최신 뉴스
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
Best Artificial Intelligence Stocks To Follow TodayJuly 22nd - MarketBeat
Why is Tempus AI stock sliding today? By Investing.com - Investing.com Canada
Tempus AI launches pharmacogenomics testing nationwide - Investing.com
Tempus AI launches pharmacogenomics testing nationwide By Investing.com - Investing.com UK
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine - Business Wire
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
Tempus AI: Buy Rating Reaffirmed as Personalis Deal Strengthens MRD Position; $75 Price Target Maintained - TipRanks
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Tempus AI buys Personalis for $1.5 billion - grafa.com
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - Stocktwits
Artificial Intelligence Stocks To Add to Your WatchlistJuly 21st - MarketBeat
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI Stock Short Interest Falls to 33.94% - Quiver Quantitative
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus AI (TEM) to Acquire Personalis in Strategic Move - GuruFocus
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Yahoo Finance
Tempus AI (TEM) Stock May Be A Bargain Despite Its 22% Slump - Yahoo Finance
Tempus AI, Inc. $TEM Stake Boosted by Amova Asset Management Americas Inc. - MarketBeat
Personalis, Inc. (PSNL) Tempus AI, Inc.M&A CallSlideshow (NASDAQ:PSNL) 2026-07-20 - Seeking Alpha
Tempus AI Stock Near 1-Year Low: Cathie Wood’s ARK Buys More While Offloading Nvidia, Meta, Other Tech Plays - Stocktwits
Jefferies reiterates Tempus AI stock rating on acquisition concerns By Investing.com - Investing.com South Africa
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink -- Barrons.com - Moomoo
Latham, Cooley Steer $1.5B Tempus Cancer Testing Deal - Law360
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL) - Stock Titan
Personalis (NASDAQ: PSNL) agrees to stock-for-stock merger with Tempus AI - Stock Titan
Tempus AI Announces Merger Agreement to Acquire Personalis - TipRanks
Jefferies reiterates Tempus AI stock rating on acquisition concerns - Investing.com
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Dea - GuruFocus
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis - MedCity News
Needham cuts Personalis stock rating on Tempus AI acquisition By Investing.com - Investing.com South Africa
Tempus finds time right for $1.5B Personalis MRD grab - BioWorld News
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal - TradingView
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis - Latham & Watkins LLP
Needham cuts Personalis stock rating on Tempus AI acquisition - Investing.com UK
Tempus to acquire cancer test maker Personalis for $1.5B - BioPharma Dive
Tempus AI stock maintains Buy rating after Personalis acquisition By Investing.com - Investing.com Australia
Tempus AI to acquire Personalis for $1.5B - The Business Journals
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal - TradingView
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink - Barron's
Tempus to buy cancer test-maker Personalis for $1.5B - MedTech Dive
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Benzinga
Market movers: AMC Entertainment, Hut 8, Domino’s Pizza, Tempus AI… - Proactive Investors
Needham reiterates Tempus AI stock rating after Personalis deal By Investing.com - Investing.com Nigeria
Tempus Ai Inc (TEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.86%
자본화:
|
볼륨(24시간):